Institutional
July 27, 2017
São Paulo Court allows the marketing of generic drug while the patent applications for the reference drug are still pending
Allergan had obtained an injunction preventing the marketing of a generic drug for Combingan®. However, such injunction was revoked because the Trial Court understood in a decision on the merits the owner of pending patent applications does not enjoy exclusive rights. The decision may be subject to an appeal.
Click on Download to access the full text of the decision.
Back
Share:
Last related news
February 14, 2025
Chambers and Partners’ Patent Litigation Guide 2025 is now available
The Patent Litigation 2025 Guide is now available! Organized by Chambers and Partners, Kasznar Leonardos has led the chapter in Brazil. Our … Chambers and Partners’ Patent Litigation Guide 2025 is now available
February 13, 2025
Kasznar Leonardos is ranked in Chambers and Partners Global Guide 2025
We are pleased to announce our recognition by the Chambers and Partners Global Guide 2025. Our firm has once again been recognized … Kasznar Leonardos is ranked in Chambers and Partners Global Guide 2025
January 31, 2025
Kasznar Leonardos is recognized by Lexology Legal Influencers Q4 2024
We are honored to announce that Kasznar Leonardos has been recognized as a leading firm in Intellectual Property in South and Central … Kasznar Leonardos is recognized by Lexology Legal Influencers Q4 2024